II

Latin America Data Center Construction Market Report 2024: Key Players Include AECOM, Aceco TI, Afonso Franca Engenharia, Quark, Zeittec, Soben, Quark, Gensler, Turner Construction and ZFB Group - ResearchAndMarkets.com

Retrieved on: 
Wednesday, May 8, 2024
Technology, Commercial Building & Real Estate, Construction & Property, Data Management, WOM, USD, World Bank, ZFB, Organization, Free-trade zone, Internet, Investment, BNPL, Information, Policy, Schneider Electric, CloudHQ, FTZ, AECOM, Ministry, Communication, Turner Construction, UPS, N+1, Fluor Corporation, Atmosphere, ABB, Growth, Jacobs Solutions, Airline

The "Latin America Data Center Construction Market - Industry Outlook & Forecast 2024-2029" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Latin America Data Center Construction Market - Industry Outlook & Forecast 2024-2029" report has been added to ResearchAndMarkets.com's offering.
  • The Latin America Data Center Construction Market was valued at USD 1.36 billion in 2023, and is projected to reach USD 2.32 billion by 2029, showcasing a CAGR of 9.25%.
  • Brazil led the Latin America data center construction market in 2023, accounting for over 40% of the market share in investments.
  • AECOM, Aceco TI, Afonso Franca Engenharia, Fluor Corporation, Jacobs Engineering, Constructora Sudamericana, Quark, Zeittec, Modular Data Centers, Soben, KMD Architects, Syska Hennessey Group, Quark, Gensler, Turner Construction, and ZFB Group are some of the key players in Latin America data center construction market.

Benefit Street Partners Closes Second Special Situations Fund

Retrieved on: 
Wednesday, May 8, 2024
Asset Management, Professional Services, Finance, Special, BSP, Investment, IRR

Benefit Street Partners L.L.C (“BSP”) announced the final close of BSP Special Situations Fund II and its affiliated vehicles (“Fund II”) which were oversubscribed with approximately $850 million in capital commitments.

Key Points: 
  • Benefit Street Partners L.L.C (“BSP”) announced the final close of BSP Special Situations Fund II and its affiliated vehicles (“Fund II”) which were oversubscribed with approximately $850 million in capital commitments.
  • Fund II will seek to continue the investment approach of its predecessor fund.
  • BSP’s special situations platform aims to provide solutions to borrowers unable to access traditional markets, leveraging its vast experience in stressed and distressed situations.
  • Since inception of the platform, the special situations team has deployed over $3 billion.

Organon Announces Pricing of $1.0 Billion Senior Notes Offering

Retrieved on: 
Wednesday, May 8, 2024
General Health, Pharmaceutical, Health, Medical Devices, Sale, Person, OGN, European Economic Area, Regulation, Credit, Note, Security (finance)

Organon (NYSE: OGN) (“Organon”), a global healthcare company with a focus on women’s health, announced today that it, together with Organon Foreign Debt Co-Issuer B.V., a direct wholly-owned subsidiary of Organon, as co-issuer (the “Co-Issuer” and, together with Organon, the “Companies”), have priced an offering of $500 million of 6.750% senior secured notes due 2034 (the “Secured Notes”) and $500 million of 7.875% senior unsecured notes due 2034 (the “Unsecured Notes” and, together with the Secured Notes the “Notes”).

Key Points: 
  • Organon (NYSE: OGN) (“Organon”), a global healthcare company with a focus on women’s health, announced today that it, together with Organon Foreign Debt Co-Issuer B.V., a direct wholly-owned subsidiary of Organon, as co-issuer (the “Co-Issuer” and, together with Organon, the “Companies”), have priced an offering of $500 million of 6.750% senior secured notes due 2034 (the “Secured Notes”) and $500 million of 7.875% senior unsecured notes due 2034 (the “Unsecured Notes” and, together with the Secured Notes the “Notes”).
  • Each series of notes will be guaranteed by each of the entities that guarantees the Companies’ existing senior secured credit facilities (the “Credit Facilities”).
  • The initial offering price to investors will be 100% of the principal amount thereof.
  • The Notes offering is expected to close on May 17, 2024, subject to customary closing conditions.

ARTBIO and Nucleus RadioPharma Announce Collaboration to Manufacture GMP-Grade Therapeutic Products Containing Radioisotope Pb-212 to Support Emerging Clinical Trials

Retrieved on: 
Tuesday, May 7, 2024
Biotechnology, Health, Radiology, Pharmaceutical, Clinical Trials, Radiopharmaceutical, Prostate cancer, Cancer, Partnership, The, Patient, Hospital, Medical imaging

Under the terms of the agreement, Nucleus will manufacture ARTBIO’s 212Pb-radiolabeled therapies for its planned Phase I and II clinical trials of its lead program in prostate cancer, AB001, using ARTBIO’s proprietary AlphaDirectTM 212Pb isolation technology.

Key Points: 
  • Under the terms of the agreement, Nucleus will manufacture ARTBIO’s 212Pb-radiolabeled therapies for its planned Phase I and II clinical trials of its lead program in prostate cancer, AB001, using ARTBIO’s proprietary AlphaDirectTM 212Pb isolation technology.
  • AlphaDirectTM is a first-of-its-kind system that delivers highly pure 212Pb from widely available raw materials.
  • 212Pb is an alpha-emitting radioisotope that has gained attention for its potential applications in therapeutic medicine, particularly in targeted alpha radioligand therapy due to the radioisotope’s attractive short half-life and other properties.
  • Preliminary studies of radiopharmaceuticals labeled with 212Pb have been promising, indicating that 212Pb has the potential to address unmet clinical needs.

Alight Names Two New Independent Directors, Dave Guilmette and Coretha Rushing, to its Board of Directors

Retrieved on: 
Monday, May 6, 2024
Software, Data Analytics, Human Resources, Internet, Finance, Professional Services, Technology, Other Technology, Sale, Agreement, HR, Research, HCM, Human, Chairperson, Simpson Thacher & Bartlett, Professional services, Port and starboard, Halshany, Growth, Management

Alight, Inc. (NYSE: ALIT) (“Alight” or the “Company”), a leading cloud-based human capital and technology services provider, today announced the appointment of Dave Guilmette and Coretha Rushing as independent directors to its Board of Directors (the “Board”), effective immediately.

Key Points: 
  • Alight, Inc. (NYSE: ALIT) (“Alight” or the “Company”), a leading cloud-based human capital and technology services provider, today announced the appointment of Dave Guilmette and Coretha Rushing as independent directors to its Board of Directors (the “Board”), effective immediately.
  • During this process, Starboard will have the ability to submit candidates for the Board’s consideration and meet final candidates.
  • William P. Foley, II, Chair of the Board, said, “We are pleased to welcome Dave and Coretha to the Board.
  • Dave and Coretha each bring a wealth of industry, operations, and governance expertise that will allow them to contribute from day one.

Organon Announces Proposed $1.0 Billion Senior Notes Offering

Retrieved on: 
Tuesday, May 7, 2024
Health, Consumer, Women, General Health, Pharmaceutical, Biotechnology, Sale, Person, OGN, European Economic Area, Regulation, Credit, Security (finance)

Organon (NYSE: OGN) (“Organon”), a global healthcare company with a focus on women’s health, announced today that it, together with Organon Foreign Debt Co-Issuer B.V., a direct wholly-owned subsidiary of Organon, as co-issuer (the “Co-Issuer” and, together with Organon, the “Companies”), plan to offer, subject to market conditions, $500 million of senior secured notes due 2034 (the “secured notes”) and $500 million of senior unsecured notes due 2034 (the “unsecured notes” and, together with the Secured Notes the “notes”).

Key Points: 
  • Organon (NYSE: OGN) (“Organon”), a global healthcare company with a focus on women’s health, announced today that it, together with Organon Foreign Debt Co-Issuer B.V., a direct wholly-owned subsidiary of Organon, as co-issuer (the “Co-Issuer” and, together with Organon, the “Companies”), plan to offer, subject to market conditions, $500 million of senior secured notes due 2034 (the “secured notes”) and $500 million of senior unsecured notes due 2034 (the “unsecured notes” and, together with the Secured Notes the “notes”).
  • Each series of notes will be guaranteed by each of the entities that guarantees the Companies’ existing senior secured credit facilities (the “Credit Facilities”).
  • The notes offering is expected to be a leverage-neutral transaction.
  • The Companies intend to use the net proceeds from the sale of the notes to repay a portion of their borrowings under the Credit Facilities’ U.S. dollar-denominated “tranche B” term loan and to pay the fees and expenses incurred in connection with the foregoing.

Electrosurgery Market to be Worth $8.99 Billion by 2031 - Exclusive Report by Meticulous Research®

Retrieved on: 
Wednesday, May 8, 2024
Smoke, United Nations, Risk, General surgery, Surgeon, Electrosurgery, Medtronic, Smith, Olympus Corporation, Boston Scientific, Lip, Perforation, Prevalence, Skin, Medical tourism, Spine, Obstetrics, Ageing, Argon, Plasma, Conditional sentence, Hospital, Generator, Geography, ENT, Johnson & Johnson, Bleeding, Incidence, Government, BPH, Stryker Corporation, Steris, ASC, Disease, United, Patient, Coagulation, Circulatory system, Cancer, Growth, Dentistry

Additionally, factors such as rising healthcare expenditure and market expansion in emerging economies are expected to create market growth opportunities.

Key Points: 
  • Additionally, factors such as rising healthcare expenditure and market expansion in emerging economies are expected to create market growth opportunities.
  • However, the risks associated with electrosurgical procedures and the shortage of surgeons restrain the growth of this market.
  • The report also includes an extensive assessment of the key growth strategies adopted by leading market players over the past three years.
  • The global electrosurgery market has witnessed several product launches, product approvals, acquisitions, and expansions in the last couple of years.

Electrosurgery Market to be Worth $8.99 Billion by 2031 - Exclusive Report by Meticulous Research®

Retrieved on: 
Wednesday, May 8, 2024
Smoke, United Nations, Risk, General surgery, Surgeon, Electrosurgery, Medtronic, Smith, Olympus Corporation, Boston Scientific, Lip, Perforation, Prevalence, Skin, Medical tourism, Spine, Obstetrics, Ageing, Argon, Plasma, Conditional sentence, Hospital, Generator, Geography, ENT, Johnson & Johnson, Bleeding, Incidence, Government, BPH, Stryker Corporation, Steris, ASC, Disease, United, Patient, Coagulation, Circulatory system, Cancer, Growth, Dentistry

Additionally, factors such as rising healthcare expenditure and market expansion in emerging economies are expected to create market growth opportunities.

Key Points: 
  • Additionally, factors such as rising healthcare expenditure and market expansion in emerging economies are expected to create market growth opportunities.
  • However, the risks associated with electrosurgical procedures and the shortage of surgeons restrain the growth of this market.
  • The report also includes an extensive assessment of the key growth strategies adopted by leading market players over the past three years.
  • The global electrosurgery market has witnessed several product launches, product approvals, acquisitions, and expansions in the last couple of years.

Tabling of the 2023-2024 annual report: Toward full implementation of the modernized Official Languages Act

Retrieved on: 
Tuesday, May 7, 2024
Use, Part, Treasury Board of Canada, Language, Policy, Languages of Ethiopia, Official Languages Act, Roadmap, Equality, Act, History, QC, Federation, Legislation, Parliament, Commissioner, Annual report, Commissioner of Official Languages

The modernization of the Official Languages Act in June 2023 marked the beginning of a new chapter not only in the history of official languages, but also in the history of the Office of the Commissioner of Official Languages.

Key Points: 
  • The modernization of the Official Languages Act in June 2023 marked the beginning of a new chapter not only in the history of official languages, but also in the history of the Office of the Commissioner of Official Languages.
  • Full implementation of the Act is necessary to ensure that the intended changes can be realized within the new federal language policy framework.
  • I'm counting on all federal institutions to step up their efforts to meet their language obligations, including the new ones in the modernized Official Languages Act."
  • In 2023–2024, the Commissioner of Official Languages received a total of 847 admissible complaints under the Official Languages Act.

Harry Hoffman and David Herbert join the HM Venture Partners team as Venture Partners

Retrieved on: 
Tuesday, May 7, 2024
Mayo Clinic, Treasurer, Insurance, Risk management, Clinical professor, New Ventures, Funding, SMCP, SAN

SAN FRANCISCO, May 7, 2024 /PRNewswire/ -- HM Venture Partners (HMVP), a global healthcare venture capital firm, is thrilled to announce that Harry Hoffman and David Herbert have joined as Venture Partners.

Key Points: 
  • SAN FRANCISCO, May 7, 2024 /PRNewswire/ -- HM Venture Partners (HMVP), a global healthcare venture capital firm, is thrilled to announce that Harry Hoffman and David Herbert have joined as Venture Partners.
  • In their roles, Harry and David will enrich team structure, broaden proprietary deal sourcing capability, and enhance growth opportunities for portfolio companies.
  • "We are extremely excited to welcome Harry and David to our firm.
  • Harry also served as Treasurer for Mayo where he oversaw issuance of debt, banking, insurance, and risk management relationships.